This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Astrazeneca (AZN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $65.53, moving -0.7% from the previous trading session.
FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld
by Zacks Equity Research
AstraZeneca's (AZN) Evusheld is no longer authorized for use in the United States after laboratory data showed that it does not neutralize Omicron subvariants.
Pharma Stock Roundup: JNJ Q4 Results Mixed, MRK Keytruda Prostate Cancer Study Ends
by Kinjel Shah
J&J (JNJ) reports mixed fourth-quarter results. Merck (MRK) discontinues an advanced prostate cancer study on blockbuster drug Keytruda for futility.
Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Volume growth from Amgen's (AMGN) key drugs like Prolia, Otezla, Repatha and others is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $66.28 in the latest trading session, marking a -1.97% move from the prior day.
The Zacks Analyst Blog Highlights AstraZeneca, NextEra Energy, The Boeing, The PNC Financial Services Group and Centene
by Zacks Equity Research
AstraZeneca, NextEra Energy, The Boeing, The PNC Financial Services Group and Centene are part of the Zacks top Analyst Blog.
Top Analyst Reports for AstraZeneca, NextEra Energy & Boeing Company
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC (AZN), NextEra Energy, Inc. (NEE) and The Boeing Company (BA).
Lilly (LLY) Jardiance Kidney Disease sNDA Gets FDA Acceptance
by Zacks Equity Research
Eli Lilly's (LLY) sNDA seeks approval for diabetes medicine, Jardiance, to reduce the risk of kidney disease progression and cardiovascular death in adults with CKD.
Astrazeneca (AZN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed at $70.74 in the latest trading session, marking a -0.48% move from the prior day.
Valneva (VALN) Stock Down 61.5% in the Past Year: Here's Why
by Zacks Equity Research
Valneva's (VALN) COVID-19 vaccine looks promising, but the European Commission's revised advance purchase agreement jeopardizes its COVID-19 vaccine program.
Biotech Stock Roundup: REGN Down on Eylea Data, CINC Surges on AZN Offer & More
by Zacks Equity Research
Updates from Regeneron (REGN) and CinCor Pharma (CINC) are the key highlights from the biotech sector during the past week.
Emergent (EBS) to Start Restructuring Plan, Lays Off 5% Workforce
by Zacks Equity Research
Once this restructuring activity is completed, Emergent BioSolutions (EBS) expects to result in annualized savings of over $60 million. It also slightly raised its total revenue guidance for 2022.
AstraZeneca (AZN) Set to Acquire CinCor Pharma for $1.3B
by Zacks Equity Research
AstraZeneca's (AZN) CinCor Pharma buyout is going to add blood pressure drug baxdrostat to its cardiorenal pipeline.
Astrazeneca (AZN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Astrazeneca (AZN) closed the most recent trading day at $70.90, moving +0.14% from the previous trading session.
Signet Jewelers and America's Car-Mart have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Signet Jewelers and America's Car-Mart have been highlighted as Zacks Bull and Bear of the Day.
FDA Accepts AstraZeneca (AZN), Sanofi's RSV Antibody BLA
by Zacks Equity Research
The FDA's decision on AstraZeneca (AZN)/Sanofi's (SNY) regulatory filing, seeking approval for using their RSV antibody in all infants, is expected in third-quarter 2023.
DocuSign and Ford Motor have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
DocuSign and Ford Motor have been highlighted as Zacks Bull and Bear of the Day.
Pharma Stock Roundup: FDA Gives Nod to RHHBY's Lunsumio, Accepts PFE Vaccine BLA
by Kinjel Shah
FDA approves Roche's (RHHBY) Lunsumio for follicular lymphoma and accepts Pfizer's (PFE) BLA for the pentavalent meningococcal vaccine candidate.
AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers
by Zacks Equity Research
The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.
Merck (MRK) Inks Deal to Develop Antibodies for Treating Cancer
by Zacks Equity Research
Merck (MRK) partners with Kelun-Biotech to develop seven antibody-drug conjugates targeting cancer indications. Merck will have an exclusive license to develop and commercialize these candidates.
The Zacks Analyst Blog Highlights Novo Nordisk, AstraZeneca, Accenture, Chubb and Roper Technologies
by Zacks Equity Research
Novo Nordisk, AstraZeneca, Accenture, Chubb and Roper Technologies are part of the Zacks top Analyst Blog.
Top Research Reports for Novo Nordisk, AstraZeneca & Accenture
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), AstraZeneca PLC (AZN) and Accenture plc (ACN).
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs
by Zacks Equity Research
The European Commission approves AstraZeneca's (AZN) two key cancer drugs Lynparza and Imfinzi for expanded use.
AstraZeneca (AZN) Gets EU Nod & CHMP Opinions for Some Drugs
by Zacks Equity Research
The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.